Geron Stock Price To Sales
| GERN Stock | USD 1.21 0.04 3.42% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Geron's long-term financial health and intrinsic value.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 29.70 | 28.22 |
Geron | Price To Sales | Build AI portfolio with Geron Stock |
Geron Company Price To Sales Analysis
Geron's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Geron Price To Sales | 6.41 X |
Most of Geron's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Geron is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Geron Price To Sales Driver Correlations
Understanding the fundamental principles of building solid financial models for Geron is extremely important. It helps to project a fair market value of Geron Stock properly, considering its historical fundamentals such as Price To Sales. Since Geron's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Geron's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Geron's interrelated accounts and indicators.
Click cells to compare fundamentals
Geron Price To Sales Historical Pattern
Today, most investors in Geron Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Geron's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's price to sales growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Geron price to sales as a starting point in their analysis.
Geron Price To Sales |
| Timeline |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Geron Price To Sales Ratio
Price To Sales Ratio |
|
Based on the latest financial disclosure, Geron has a Price To Sales of 6.4079 times. This is 70.06% lower than that of the Biotechnology sector and 93.49% lower than that of the Health Care industry. The price to sales for all United States stocks is 43.89% higher than that of the company.
Geron Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Geron's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Geron could also be used in its relative valuation, which is a method of valuing Geron by comparing valuation metrics of similar companies.Geron is currently under evaluation in price to sales category among its peers.
Geron Current Valuation Drivers
We derive many important indicators used in calculating different scores of Geron from analyzing Geron's financial statements. These drivers represent accounts that assess Geron's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Geron's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 431.6M | 399.7M | 921.5M | 1.2B | 2.3B | 2.4B | |
| Enterprise Value | 451.1M | 419.8M | 920.0M | 1.2B | 2.3B | 2.4B |
Geron Fundamentals
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (1.20) % | ||||
| Operating Margin | (0.42) % | ||||
| Current Valuation | 473.28 M | ||||
| Shares Outstanding | 636.92 M | ||||
| Shares Owned By Insiders | 0.09 % | ||||
| Shares Owned By Institutions | 81.79 % | ||||
| Number Of Shares Shorted | 67.96 M | ||||
| Price To Earning | (12.48) X | ||||
| Price To Book | 2.79 X | ||||
| Price To Sales | 6.41 X | ||||
| Revenue | 76.99 M | ||||
| Gross Profit | 9.38 M | ||||
| EBITDA | (154.85 M) | ||||
| Net Income | (174.57 M) | ||||
| Cash And Equivalents | 219.29 M | ||||
| Cash Per Share | 0.58 X | ||||
| Total Debt | 121.72 M | ||||
| Debt To Equity | 0.39 % | ||||
| Current Ratio | 4.85 X | ||||
| Book Value Per Share | 0.42 X | ||||
| Cash Flow From Operations | (218.62 M) | ||||
| Short Ratio | 7.17 X | ||||
| Earnings Per Share | (0.21) X | ||||
| Price To Earnings To Growth | (2.38) X | ||||
| Target Price | 3.39 | ||||
| Number Of Employees | 229 | ||||
| Beta | 0.65 | ||||
| Market Capitalization | 745.19 M | ||||
| Total Asset | 594.46 M | ||||
| Retained Earnings | (1.77 B) | ||||
| Working Capital | 402.69 M | ||||
| Current Asset | 115.89 M | ||||
| Current Liabilities | 6.63 M | ||||
| Net Asset | 594.46 M |
About Geron Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Geron's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Geron using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Geron based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Geron
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Geron position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Geron will appreciate offsetting losses from the drop in the long position's value.Moving against Geron Stock
| 0.62 | VALN | Valneva SE ADR Earnings Call Next Week | PairCorr |
| 0.59 | DNTH | Dianthus Therapeutics | PairCorr |
| 0.53 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.51 | VIVS | VivoSim Labs, Symbol Change | PairCorr |
| 0.48 | DRRX | Durect | PairCorr |
The ability to find closely correlated positions to Geron could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Geron when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Geron - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Geron to buy it.
The correlation of Geron is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Geron moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Geron moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Geron can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Geron Piotroski F Score and Geron Altman Z Score analysis. To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Geron. If investors know Geron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Geron listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.21) | Revenue Per Share | Quarterly Revenue Growth 129.273 | Return On Assets | Return On Equity |
The market value of Geron is measured differently than its book value, which is the value of Geron that is recorded on the company's balance sheet. Investors also form their own opinion of Geron's value that differs from its market value or its book value, called intrinsic value, which is Geron's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Geron's market value can be influenced by many factors that don't directly affect Geron's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Geron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Geron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Geron's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.